Your browser doesn't support javascript.
loading
Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management.
Merzkani, Massini A; Bentall, Andrew J; Smith, Byron H; Benavides Lopez, Xiomara; D'Costa, Matthew R; Park, Walter D; Kremers, Walter K; Issa, Naim; Rule, Andrew D; Chakkera, Harini; Reddy, Kunam; Khamash, Hasan; Wadei, Hani M; Mai, Martin; Alexander, Mariam P; Amer, Hatem; Kukla, Aleksandra; El Ters, Mireille; Schinstock, Carrie A; Gandhi, Manish J; Heilman, Raymond; Stegall, Mark D.
Afiliación
  • Merzkani MA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Bentall AJ; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • Smith BH; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Benavides Lopez X; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • D'Costa MR; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Park WD; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • Kremers WK; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Issa N; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • Rule AD; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • Chakkera H; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Reddy K; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Khamash H; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Wadei HM; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
  • Mai M; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Alexander MP; Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ.
  • Amer H; Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ.
  • Kukla A; Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ.
  • El Ters M; Division of Transplant Surgery, Mayo Clinic, Scottsdale, AZ.
  • Schinstock CA; Division of Transplant Surgery, Mayo Clinic, Scottsdale, AZ.
  • Gandhi MJ; Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL.
  • Heilman R; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Stegall MD; William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
Transplant Direct ; 8(2): e1273, 2022 Feb.
Article en En | MEDLINE | ID: mdl-35047660
ABSTRACT

BACKGROUND:

Improving both patient and graft survival after kidney transplantation are major unmet needs. The goal of this study was to assess risk factors for specific causes of graft loss to determine to what extent patients who develop either death with a functioning graft (DWFG) or graft failure (GF) have similar baseline risk factors for graft loss.

METHODS:

We retrospectively studied all solitary renal transplants performed between January 1, 2006, and December 31, 2018, at 3 centers and determined the specific causes of DWFG and GF. We examined outcomes in different subgroups using competing risk estimates and cause-specific Cox models.

RESULTS:

Of the 5752 kidney transplants, graft loss occurred in 21.6% (1244) patients, including 12.0% (691) DWFG and 9.6% (553) GF. DWFG was most commonly due to malignancy (20.0%), infection (19.7%), cardiac disease (12.6%) with risk factors of older age and pretransplant dialysis, and diabetes as the cause of renal failure. For GF, alloimmunity (38.7%), glomerular diseases (18.6%), and tubular injury (13.9%) were the major causes. Competing risk incidence models identified diabetes and older recipients with higher rates of both DWFG and nonalloimmune GF.

CONCLUSIONS:

These data suggest that at baseline, 2 distinct populations can be identified who are at high risk for renal allograft loss a younger, nondiabetic patient group who develops GF due to alloimmunity and an older, more commonly diabetic population who develops DWFG and GF due to a mixture of causes-many nonalloimmune. Individualized management is needed to improve long-term renal allograft survival in the latter group.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transplant Direct Año: 2022 Tipo del documento: Article País de afiliación: Mongolia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transplant Direct Año: 2022 Tipo del documento: Article País de afiliación: Mongolia
...